AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02452892 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LFMS
Description: Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
Study NCT02452892 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LFMS
Description: Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
Study NCT02534428 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wool clothing
Description: superfine merino wool ensembles for baby wear
Study NCT02534428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wool clothing
Description: superfine merino wool ensembles for baby wear
Study NCT03085160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning to Breathe
Description: Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
Study NCT03085160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
Study NCT02996266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management
Description: Prophylactic normothermia
Study NCT02996266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: No intervention to control temperature unless fever occurs
Study NCT02688452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Unmodified Placebo Water
Study NCT02688452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Electrokinetically modified water (EMW)
Study NCT02003092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-5902
Description: escalating doses (mg)
Study NCT04555694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate
Description: Used to treat inflammation of the eye
Study NCT04555694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert
Description: Used to treat inflammation of the eye
Study NCT03968276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: use of digital tablet
Description: At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool.
Study NCT01655199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination ipratropium/salbutamol or placebo (nebulization)
Description: For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
Study NCT03161509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: single dose of 1 gr paracetamol
Study NCT03161509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)
Description: Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
Study NCT03627299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg glecaprevir/pibrentasivir 120mg
Description: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
Study NCT01128673 — intervention group
Intervention type: DEVICE
Intervention: mRI
Study NCT03323502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP Specialist Program
Description: New structured role with responsibility for ACP
Study NCT01718223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo interstitial photodynamic therapy using temoporfin
Study NCT01718223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection
Study NCT01718223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01718223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temoporfin
Description: Undergo interstitial photodynamic therapy using temoporfin
Study NCT04376788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: exchange blood transfusion from normal donor
Description: IV method
Study NCT04376788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plasma from convalescent patients with COVID-19
Description: IV method
Study NCT04376788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue 5 MG/ML
Description: IV method
Study NCT03029585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac® 100 mg/m2
Description: Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Study NCT03029585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac® 200 mg/m2
Description: Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Study NCT03029585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac® 300 mg/m2
Description: Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Study NCT03029585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac® 400 mg/m2
Description: Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Study NCT03029585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Intravenous Chemotherapy
Description: Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Study NCT03029585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Intravenous Chemotherapy
Description: Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Study NCT02540915 — intervention group
Intervention type: OTHER
Intervention: Standard of Care - Registry
Description: Standard of Care - Registry
Study NCT02301507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cell phone SMS text messaging
Description: This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
Study NCT04543669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel®
Description: Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
Study NCT01000935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
Study NCT04690309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with human insulin preparations or treatment with insulin analogues
Description: The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting \< 100 mg/dl (5.5 mmol/L) and postprandial \< 140 mg/dl (7.8mmol/L)
Study NCT02240810 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention (Promus PREMIER)
Description: Interventional coronary artery stenting with Promus PREMIER study stent.
Study NCT00470756 — intervention group
Intervention type: OTHER
Intervention: mechanical triggering of peroneal activity
Description: mechanical triggering of peroneal activity
Study NCT03100851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota
Description: a bottle of 100 mililiter probiotic dairy beverage containing 10\^8 CFU Lactobacillus casei strain Shirota every day after lunch.
Study NCT01185340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Study NCT01185340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01185340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01185340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
Study NCT01185340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
Study NCT02144285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3113593
Description: Administered IV
Study NCT02144285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3113593
Description: Administered SC
Study NCT02144285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study NCT02144285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02808676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Dose: 10000 IU, three times per week, orally.
Study NCT02808676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises (E)
Description: All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
Study NCT02808676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Description: CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
Study NCT02808676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo D3
Description: matching placebo for Vitamin D3
Study NCT02808676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo D3
Description: matching placebo for Vitamin D3
Study NCT02808676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control cognitive training
Description: As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
Study NCT02808676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control cognitive training
Description: As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
Study NCT02808676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo exercise
Description: As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
Study NCT02741921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight DL
Description: intubation using VivaSight DL tube
Study NCT02741921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional double-lumen tube
Description: intubation using conventional double-lumen tube
Study NCT02802176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOcell device
Description: intra-vaginal culture of embryos using INVOcell device
Study NCT02802176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional IVF
Description: traditional culture of embryos in-vitro
Study NCT01752816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Study NCT01752816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Study NCT04246905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane
Description: To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
Study NCT04246905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placedo
Description: To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
Study NCT04246905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: selective 5 - HT reuptake inhibitors (SSRI)
Description: To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
Study NCT04246905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: selective 5 - HT reuptake inhibitors (SSRI)
Description: To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
Study NCT04135183 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: changes of Pneumonia Severity Score
Description: assessing effectiveness of CAP treatment by using continuous pneumonia severity score
Study NCT02707328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02707328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Study NCT02707328 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Study NCT03843983 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lipiflow® application
Description: Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment.
Study NCT00806728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
Study NCT01848483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIDS EPC Package plus MI
Description: 1. Motivational Interviewing: In MI session #1, the nurse will set the agenda \& ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 \& 4, the nurse will also introduce advance care planning.~2. EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic \& conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation \& coordination of care.
Study NCT01848483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
Study NCT01848483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
Study NCT00947895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: IV 1000 mg daily for 3 days
Study NCT00947895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: IM ACTH 80 mg/day for 5 days.
Study NCT00947895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV placebo
Description: IV placebo (saline) daily for 3 days.
Study NCT00947895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IM placebo
Description: IM placebo (saline) daily for 5 days.
Study NCT03327025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education counseling
Description: Health education counseling
Study NCT03943771 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anxiety, renal anatomy and surgery questionnaires
Description: The day before surgery, all the patients will be visited by a member of the investigator team for preoperative consultation and will be given a questionnaire evaluating their anxiety based on STAI and VAS scores. The two experimental groups will be offered their renal modelization to be manipulated (virtually or physically) before the questionnaire.~A second survey assessing basic renal anatomy and surgery understanding will also be completed by the patients.~Anxiolytics prescription prior to surgery will be collected inside the medical file.